Document is current
Any future updates will be listed below
-
Authors
Aris, Kevin D. P.
Cofsky, Joshua C. https://orcid.org/0000-0001-5403-8555
Shi, Honglue https://orcid.org/0000-0003-3847-1652
Al-Sayyad, Noor
Ivanov, Ivan E. https://orcid.org/0000-0001-6389-0213
Balaji, Ashwin https://orcid.org/0000-0002-0075-4203
Doudna, Jennifer A. https://orcid.org/0000-0001-9161-999X
Bryant, Zev https://orcid.org/0000-0001-6751-3693
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM106159)
- License Information
-
More Information
Article History
Received: 14 February 2024
Accepted: 28 February 2025
First Online: 26 March 2025
Change Date: 22 April 2025
Change Type: Update
Change Details: In this article the affiliation ‘Chan Zuckerberg Biohub, San Francisco, CA, USA.’ was incorrectly assigned for Zev Bryant. The original article has been corrected.
Competing interests
: The Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D, though no new patents filed based on the specific findings reported in this manuscript. J.A.D. is a cofounder of Azalea Therapeutics, Caribou Biosciences, Editas Medicine, Evercrisp, Scribe Therapeutics, Intellia Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member at Evercrisp, Caribou Biosciences, Intellia Therapeutics, Scribe Therapeutics, Mammoth Biosciences, The Column Group, and Inari. J.A.D. is Chief Science Advisor to Sixth Street; is a Director at Johnson & Johnson, Altos, and Tempus; and has a research project sponsored by Apple Tree Partners. The remaining authors declare no competing interests.
